Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
SDZNY
)
41.47
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SDZNY
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 05, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025
From
Sandoz Group
Via
GlobeNewswire
Francisco Ballester to retire; Peter Stenico appointed President Region International
February 03, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
December 17, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
November 15, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
October 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
October 11, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024
From
Sandoz Group
Via
GlobeNewswire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports first quarter 2024 sales
May 07, 2024
From
Sandoz Group
Via
GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
March 13, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz announces nominations to the Board of Directors and leadership change
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
February 29, 2024
From
Sandoz Group
Via
GlobeNewswire
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
October 09, 2023
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.
Via
MarketBeat
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.